JP6340366B2 - 運動ニューロン疾患を診断および処置する方法 - Google Patents

Info

Publication number

JP6340366B2

JP6340366B2 JP2015524902A JP2015524902A JP6340366B2 JP 6340366 B2 JP6340366 B2 JP 6340366B2 JP 2015524902 A JP2015524902 A JP 2015524902A JP 2015524902 A JP2015524902 A JP 2015524902A JP 6340366 B2 JP6340366 B2 JP 6340366B2

Authority

JP

Japan

Prior art keywords

als

mir

mirna

mnd

group

Prior art date

2012-07-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 208000005264 motor neuron disease Diseases 0.000 title claims description 94
• 208000026072 Motor neurone disease Diseases 0.000 title claims description 84
• 238000000034 method Methods 0.000 title claims description 83
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 147
• 239000003795 chemical substances by application Substances 0.000 claims description 52
• 210000002161 motor neuron Anatomy 0.000 claims description 52
• IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims description 48
• 230000014509 gene expression Effects 0.000 claims description 46
• 229960002549 enoxacin Drugs 0.000 claims description 39
• 239000008194 pharmaceutical composition Substances 0.000 claims description 27
• 238000011282 treatment Methods 0.000 claims description 25
• 150000001875 compounds Chemical class 0.000 claims description 22
• 239000004480 active ingredient Substances 0.000 claims description 21
• 239000003814 drug Substances 0.000 claims description 21
• 108090000623 proteins and genes Proteins 0.000 claims description 21
• 230000035772 mutation Effects 0.000 claims description 15
• 230000004060 metabolic process Effects 0.000 claims description 14
• FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 11
• 238000003745 diagnosis Methods 0.000 claims description 10
• 230000000750 progressive effect Effects 0.000 claims description 9
• 229960004181 riluzole Drugs 0.000 claims description 9
• 208000002320 spinal muscular atrophy Diseases 0.000 claims description 7
• 239000005022 packaging material Substances 0.000 claims description 6
• 230000003827 upregulation Effects 0.000 claims description 6
• 239000012190 activator Substances 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 206010006542 Bulbar palsy Diseases 0.000 claims description 4
• 206010028289 Muscle atrophy Diseases 0.000 claims description 4
• 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 4
• 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 4
• 201000010901 lateral sclerosis Diseases 0.000 claims description 4
• 230000020763 muscle atrophy Effects 0.000 claims description 4
• 201000000585 muscular atrophy Diseases 0.000 claims description 4
• 201000002241 progressive bulbar palsy Diseases 0.000 claims description 4
• 201000000196 pseudobulbar palsy Diseases 0.000 claims description 4
• 229940124597 therapeutic agent Drugs 0.000 claims description 4
• 239000003085 diluting agent Substances 0.000 claims description 3
• 238000007639 printing Methods 0.000 claims description 3
• 239000002679 microRNA Substances 0.000 description 141
• 108700011259 MicroRNAs Proteins 0.000 description 90
• 125000000217 alkyl group Chemical group 0.000 description 45
• 238000012545 processing Methods 0.000 description 43
• -1 quinolone compound Chemical class 0.000 description 38
• 125000003118 aryl group Chemical group 0.000 description 31
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
• 210000004027 cell Anatomy 0.000 description 29
• 201000010099 disease Diseases 0.000 description 25
• 239000003623 enhancer Substances 0.000 description 25
• 108091070501 miRNA Proteins 0.000 description 25
• 125000000547 substituted alkyl group Chemical group 0.000 description 25
• 102000003890 RNA-binding protein FUS Human genes 0.000 description 22
• 108090000292 RNA-binding protein FUS Proteins 0.000 description 22
• 239000000203 mixture Substances 0.000 description 22
• 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 21
• 101710150875 TAR DNA-binding protein 43 Proteins 0.000 description 21
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
• 102100023387 Endoribonuclease Dicer Human genes 0.000 description 18
• 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 18
• 241000282414 Homo sapiens Species 0.000 description 17
• 230000000694 effects Effects 0.000 description 17
• 210000003205 muscle Anatomy 0.000 description 17
• 210000001519 tissue Anatomy 0.000 description 17
• 241000699670 Mus sp. Species 0.000 description 15
• 125000000753 cycloalkyl group Chemical group 0.000 description 15
• LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 15
• 125000003107 substituted aryl group Chemical group 0.000 description 15
• 125000004432 carbon atom Chemical group C* 0.000 description 14
• 229940079593 drug Drugs 0.000 description 14
• 229910052739 hydrogen Inorganic materials 0.000 description 14
• 239000002243 precursor Substances 0.000 description 14
• 108091030071 RNAI Proteins 0.000 description 12
• 125000003545 alkoxy group Chemical group 0.000 description 12
• 230000009368 gene silencing by RNA Effects 0.000 description 12
• 239000000523 sample Substances 0.000 description 12
• 239000000126 substance Substances 0.000 description 11
• 238000012360 testing method Methods 0.000 description 11
• 238000004458 analytical method Methods 0.000 description 10
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
• 230000004770 neurodegeneration Effects 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
• 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 9
• 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 9
• 230000001086 cytosolic effect Effects 0.000 description 9
• 230000002708 enhancing effect Effects 0.000 description 9
• 125000005843 halogen group Chemical group 0.000 description 9
• 210000005036 nerve Anatomy 0.000 description 9
• 229910052760 oxygen Inorganic materials 0.000 description 9
• 229910052717 sulfur Inorganic materials 0.000 description 9
• 125000002252 acyl group Chemical group 0.000 description 8
• 125000004429 atom Chemical group 0.000 description 8
• 210000004556 brain Anatomy 0.000 description 8
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 8
• 125000004122 cyclic group Chemical group 0.000 description 8
• 230000003828 downregulation Effects 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 210000000278 spinal cord Anatomy 0.000 description 8
• 108091032955 Bacterial small RNA Proteins 0.000 description 7
• 125000002947 alkylene group Chemical group 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 108020004999 messenger RNA Proteins 0.000 description 7
• 229910052757 nitrogen Inorganic materials 0.000 description 7
• 102000004169 proteins and genes Human genes 0.000 description 7
• 230000001105 regulatory effect Effects 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 241001465754 Metazoa Species 0.000 description 6
• 125000003282 alkyl amino group Chemical group 0.000 description 6
• 238000010171 animal model Methods 0.000 description 6
• 125000003710 aryl alkyl group Chemical group 0.000 description 6
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
• 230000008499 blood brain barrier function Effects 0.000 description 6
• 229910052799 carbon Inorganic materials 0.000 description 6
• 210000001671 embryonic stem cell Anatomy 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 125000001072 heteroaryl group Chemical group 0.000 description 6
• 239000001257 hydrogen Substances 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 238000010172 mouse model Methods 0.000 description 6
• 239000002773 nucleotide Substances 0.000 description 6
• 125000003729 nucleotide group Chemical group 0.000 description 6
• 239000001301 oxygen Substances 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 108091033319 polynucleotide Proteins 0.000 description 6
• 239000002157 polynucleotide Substances 0.000 description 6
• 102000040430 polynucleotide Human genes 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 229920006395 saturated elastomer Polymers 0.000 description 6
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 101000869796 Homo sapiens Microprocessor complex subunit DGCR8 Proteins 0.000 description 5
• 102100032459 Microprocessor complex subunit DGCR8 Human genes 0.000 description 5
• 108091080995 Mir-9/mir-79 microRNA precursor family Proteins 0.000 description 5
• 208000012902 Nervous system disease Diseases 0.000 description 5
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
• 238000010364 biochemical engineering Methods 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 239000008298 dragée Substances 0.000 description 5
• 230000008482 dysregulation Effects 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 230000030279 gene silencing Effects 0.000 description 5
• 108091047084 miR-9 stem-loop Proteins 0.000 description 5
• 208000015122 neurodegenerative disease Diseases 0.000 description 5
• 239000011593 sulfur Substances 0.000 description 5
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
• GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 4
• 102000014914 Carrier Proteins Human genes 0.000 description 4
• 201000011240 Frontotemporal dementia Diseases 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• 206010056677 Nerve degeneration Diseases 0.000 description 4
• 208000025966 Neurological disease Diseases 0.000 description 4
• 102000044126 RNA-Binding Proteins Human genes 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 125000003342 alkenyl group Chemical group 0.000 description 4
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
• 239000003242 anti bacterial agent Substances 0.000 description 4
• 125000002102 aryl alkyloxo group Chemical group 0.000 description 4
• 125000004104 aryloxy group Chemical group 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 108091008324 binding proteins Proteins 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 229960003405 ciprofloxacin Drugs 0.000 description 4
• 125000004663 dialkyl amino group Chemical group 0.000 description 4
• USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
• DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 229960003722 doxycycline Drugs 0.000 description 4
• XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 4
• 239000003651 drinking water Substances 0.000 description 4
• 235000020188 drinking water Nutrition 0.000 description 4
• 238000002567 electromyography Methods 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 125000000524 functional group Chemical group 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 229910052736 halogen Inorganic materials 0.000 description 4
• 150000002367 halogens Chemical class 0.000 description 4
• 150000002430 hydrocarbons Chemical group 0.000 description 4
• 150000002431 hydrogen Chemical class 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 230000035800 maturation Effects 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 230000000926 neurological effect Effects 0.000 description 4
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
• 230000030147 nuclear export Effects 0.000 description 4
• 229960001699 ofloxacin Drugs 0.000 description 4
• 230000008506 pathogenesis Effects 0.000 description 4
• 230000000144 pharmacologic effect Effects 0.000 description 4
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
• 102220020162 rs397508045 Human genes 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 230000009261 transgenic effect Effects 0.000 description 4
• 230000032258 transport Effects 0.000 description 4
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 101000664887 Homo sapiens Superoxide dismutase [Cu-Zn] Proteins 0.000 description 3
• 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 108700020471 RNA-Binding Proteins Proteins 0.000 description 3
• 108010057163 Ribonuclease III Proteins 0.000 description 3
• 102000003661 Ribonuclease III Human genes 0.000 description 3
• 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 3
• 238000000692 Student's t-test Methods 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
• 102100021947 Survival motor neuron protein Human genes 0.000 description 3
• 125000004442 acylamino group Chemical group 0.000 description 3
• 125000000304 alkynyl group Chemical group 0.000 description 3
• 201000008257 amyotrophic lateral sclerosis type 1 Diseases 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 210000000133 brain stem Anatomy 0.000 description 3
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
• 238000012937 correction Methods 0.000 description 3
• ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 3
• 210000000805 cytoplasm Anatomy 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 3
• 230000004064 dysfunction Effects 0.000 description 3
• 229940124307 fluoroquinolone Drugs 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 229930195733 hydrocarbon Natural products 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 238000002595 magnetic resonance imaging Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 108091028606 miR-1 stem-loop Proteins 0.000 description 3
• 108091007426 microRNA precursor Proteins 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 125000004433 nitrogen atom Chemical group N* 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 108091007428 primary miRNA Proteins 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 238000004445 quantitative analysis Methods 0.000 description 3
• 150000007660 quinolones Chemical class 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 125000001424 substituent group Chemical group 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• JHNURUNMNRSGRO-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-3-ylmethanamine Chemical compound C1=CC=C2OC(CN)COC2=C1 JHNURUNMNRSGRO-UHFFFAOYSA-N 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical group C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
• 102000007469 Actins Human genes 0.000 description 2
• 108010085238 Actins Proteins 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 239000004215 Carbon black (E152) Substances 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• 102000047351 Exportin-5 Human genes 0.000 description 2
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
• IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 2
• 101000847058 Homo sapiens Exportin-5 Proteins 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 208000029578 Muscle disease Diseases 0.000 description 2
• UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
• 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
• 238000011529 RT qPCR Methods 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 102000019197 Superoxide Dismutase Human genes 0.000 description 2
• 108010012715 Superoxide dismutase Proteins 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 208000026481 Werdnig-Hoffmann disease Diseases 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 125000004423 acyloxy group Chemical group 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 125000000278 alkyl amino alkyl group Chemical group 0.000 description 2
• 125000005115 alkyl carbamoyl group Chemical group 0.000 description 2
• 125000004414 alkyl thio group Chemical group 0.000 description 2
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
• 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
• 125000005239 aroylamino group Chemical group 0.000 description 2
• 125000005110 aryl thio group Chemical group 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
• 239000012965 benzophenone Substances 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• BEWYHVAWEKZDPP-UHFFFAOYSA-N bornane Chemical compound C1CC2(C)CCC1C2(C)C BEWYHVAWEKZDPP-UHFFFAOYSA-N 0.000 description 2
• 230000006931 brain damage Effects 0.000 description 2
• 231100000874 brain damage Toxicity 0.000 description 2
• 208000029028 brain injury Diseases 0.000 description 2
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
• 229960002802 bromocriptine Drugs 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 125000000392 cycloalkenyl group Chemical group 0.000 description 2
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
• MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
• NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
• 229960000958 deferoxamine Drugs 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 2
• 229960001395 fenbufen Drugs 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 2
• 229960004675 fusidic acid Drugs 0.000 description 2
• 230000005021 gait Effects 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
• 102000056070 human SOD1 Human genes 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• 238000007901 in situ hybridization Methods 0.000 description 2
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 238000007914 intraventricular administration Methods 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical group C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
• 150000004702 methyl esters Chemical class 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 108091056924 miR-124 stem-loop Proteins 0.000 description 2
• 108091063796 miR-206 stem-loop Proteins 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 230000037023 motor activity Effects 0.000 description 2
• 230000002232 neuromuscular Effects 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
• 229960001180 norfloxacin Drugs 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• 210000002381 plasma Anatomy 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• 238000003753 real-time PCR Methods 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• 229940072169 rilutek Drugs 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 101150062190 sod1 gene Proteins 0.000 description 2
• 208000019929 sporadic amyotrophic lateral sclerosis Diseases 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 2
• 229960003087 tioguanine Drugs 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 238000011491 transcranial magnetic stimulation Methods 0.000 description 2
• 238000011830 transgenic mouse model Methods 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 2
• 229960001128 triprolidine Drugs 0.000 description 2
• 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 2
• 208000032527 type III spinal muscular atrophy Diseases 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
• DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
• CYEZJYAMLNTSKN-VOTSOKGWSA-N (e)-2-methylhept-3-ene Chemical compound CCC\C=C\C(C)C CYEZJYAMLNTSKN-VOTSOKGWSA-N 0.000 description 1
• GQMMRLBWXCGBEV-YVMONPNESA-N (nz)-n-[(3-nitrophenyl)methylidene]hydroxylamine Chemical compound O\N=C/C1=CC=CC([N+]([O-])=O)=C1 GQMMRLBWXCGBEV-YVMONPNESA-N 0.000 description 1
• JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• XJIRSLHMKBUGMR-UHFFFAOYSA-N 1-ethylsulfanylbutane Chemical compound CCCCSCC XJIRSLHMKBUGMR-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
• IEMMBWWQXVXBEU-UHFFFAOYSA-N 2-acetylfuran Chemical group CC(=O)C1=CC=CO1 IEMMBWWQXVXBEU-UHFFFAOYSA-N 0.000 description 1
• HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical group C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
• 108020005345 3' Untranslated Regions Proteins 0.000 description 1
• DQQNMIPXXNPGCV-UHFFFAOYSA-N 3-hexyne Chemical compound CCC#CCC DQQNMIPXXNPGCV-UHFFFAOYSA-N 0.000 description 1
• QMYGFTJCQFEDST-UHFFFAOYSA-N 3-methoxybutyl acetate Chemical group COC(C)CCOC(C)=O QMYGFTJCQFEDST-UHFFFAOYSA-N 0.000 description 1
• 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
• WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 description 1
• 208000000187 Abnormal Reflex Diseases 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 101710159080 Aconitate hydratase A Proteins 0.000 description 1
• 101710159078 Aconitate hydratase B Proteins 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 102100022987 Angiogenin Human genes 0.000 description 1
• 108010064733 Angiotensins Proteins 0.000 description 1
• 108020000946 Bacterial DNA Proteins 0.000 description 1
• SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 206010008027 Cerebellar atrophy Diseases 0.000 description 1
• 208000007190 Chlamydia Infections Diseases 0.000 description 1
• 241000723346 Cinnamomum camphora Species 0.000 description 1
• 208000032862 Clinical Deterioration Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 102000004420 Creatine Kinase Human genes 0.000 description 1
• 108010042126 Creatine kinase Proteins 0.000 description 1
• 108010041052 DNA Topoisomerase IV Proteins 0.000 description 1
• 108090000133 DNA helicases Proteins 0.000 description 1
• 102000003844 DNA helicases Human genes 0.000 description 1
• 230000004543 DNA replication Effects 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• HDWLUGYOLUHEMN-UHFFFAOYSA-N Dinobuton Chemical compound CCC(C)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1OC(=O)OC(C)C HDWLUGYOLUHEMN-UHFFFAOYSA-N 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 108010093099 Endoribonucleases Proteins 0.000 description 1
• 102000002494 Endoribonucleases Human genes 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Chemical group 0.000 description 1
• 206010051267 Facial paresis Diseases 0.000 description 1
• 208000001914 Fragile X syndrome Diseases 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 101000757236 Homo sapiens Angiogenin Proteins 0.000 description 1
• 101000693844 Homo sapiens Insulin-like growth factor-binding protein complex acid labile subunit Proteins 0.000 description 1
• 101000836337 Homo sapiens Probable helicase senataxin Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 1
• XETQTCAMTVHYPO-UHFFFAOYSA-N Isocamphan von ungewisser Konfiguration Natural products C1CC2C(C)(C)C(C)C1C2 XETQTCAMTVHYPO-UHFFFAOYSA-N 0.000 description 1
• 208000011823 Juvenile amyotrophic lateral sclerosis Diseases 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
• 108091007773 MIR100 Proteins 0.000 description 1
• 108091007774 MIR107 Proteins 0.000 description 1
• 206010026749 Mania Diseases 0.000 description 1
• 108091007780 MiR-122 Proteins 0.000 description 1
• 108091028080 MiR-132 Proteins 0.000 description 1
• 108091093073 MiR-134 Proteins 0.000 description 1
• 108091034054 MiR-138 Proteins 0.000 description 1
• 108091093142 MiR-144 Proteins 0.000 description 1
• 108091093082 MiR-146 Proteins 0.000 description 1
• 108091046841 MiR-150 Proteins 0.000 description 1
• 108091033433 MiR-191 Proteins 0.000 description 1
• 108091028141 MiR-203 Proteins 0.000 description 1
• 108091028695 MiR-224 Proteins 0.000 description 1
• 108091007419 MiR-27 Proteins 0.000 description 1
• 108091081013 MiR-33 Proteins 0.000 description 1
• 108091028066 Mir-126 Proteins 0.000 description 1
• 108091028076 Mir-127 Proteins 0.000 description 1
• 108091060568 Mir-133 microRNA precursor family Proteins 0.000 description 1
• 108091028684 Mir-145 Proteins 0.000 description 1
• 108091028232 Mir-184 Proteins 0.000 description 1
• 108091062154 Mir-205 Proteins 0.000 description 1
• 108091062170 Mir-22 Proteins 0.000 description 1
• 108091060585 Mir-31 Proteins 0.000 description 1
• 108091027559 Mir-96 microRNA Proteins 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 208000010428 Muscle Weakness Diseases 0.000 description 1
• 206010049565 Muscle fatigue Diseases 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 206010028372 Muscular weakness Diseases 0.000 description 1
• 108010088373 Neurofilament Proteins Proteins 0.000 description 1
• 102000008763 Neurofilament Proteins Human genes 0.000 description 1
• 241000380800 Nordus Species 0.000 description 1
• 102000007999 Nuclear Proteins Human genes 0.000 description 1
• 108010089610 Nuclear Proteins Proteins 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000027089 Parkinsonian disease Diseases 0.000 description 1
• 206010034010 Parkinsonism Diseases 0.000 description 1
• 108091060552 Pasha (protein) Proteins 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 102100027178 Probable helicase senataxin Human genes 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 108090000944 RNA Helicases Proteins 0.000 description 1
• 102000004409 RNA Helicases Human genes 0.000 description 1
• 238000010802 RNA extraction kit Methods 0.000 description 1
• 101710105008 RNA-binding protein Proteins 0.000 description 1
• 102100029547 Ras-related protein Rab-39B Human genes 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• NJCJBUHJQLFDSW-UHFFFAOYSA-N Rufloxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 NJCJBUHJQLFDSW-UHFFFAOYSA-N 0.000 description 1
• 101150081851 SMN1 gene Proteins 0.000 description 1
• 108700013394 SOD1 G93A Proteins 0.000 description 1
• 238000011831 SOD1-G93A transgenic mouse Methods 0.000 description 1
• 101000720976 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ATP-dependent helicase dcr1 Proteins 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 208000029033 Spinal Cord disease Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 1
• 241000425573 Talanes Species 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 208000010641 Tooth disease Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 208000028933 Waisman syndrome Diseases 0.000 description 1
• 208000010206 X-Linked Mental Retardation Diseases 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• FJIIOEQLAAKWEL-VISHRWGOSA-N acetic acid [(1R,5R,8S,12aR)-1-(3-furanyl)-8-hydroxy-4b,7,7,10a,12a-pentamethyl-3-oxo-1,5,6,6a,8,9,10,10b,11,12-decahydronaphtho[2,1-f][2]benzopyran-5-yl] ester Chemical compound C=1([C@H]2[C@]3(C)CCC4C5(C)CC[C@H](O)C(C)(C)C5C[C@H](C4(C3=CC(=O)O2)C)OC(=O)C)C=COC=1 FJIIOEQLAAKWEL-VISHRWGOSA-N 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 229940040563 agaric acid Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
• 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 230000001773 anti-convulsant effect Effects 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 229960003965 antiepileptics Drugs 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 125000003435 aroyl group Chemical group 0.000 description 1
• 125000005251 aryl acyl group Chemical group 0.000 description 1
• 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
• 125000001769 aryl amino group Chemical group 0.000 description 1
• 239000000305 astragalus gummifer gum Substances 0.000 description 1
• 210000003050 axon Anatomy 0.000 description 1
• 125000003943 azolyl group Chemical group 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• 230000027455 binding Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 229930006742 bornane Natural products 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 229930008380 camphor Natural products 0.000 description 1
• 229960000846 camphor Drugs 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 230000001713 cholinergic effect Effects 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 125000006165 cyclic alkyl group Chemical group 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
• 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 238000012350 deep sequencing Methods 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000005786 degenerative changes Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 230000002638 denervation Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000011833 dog model Methods 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 239000013583 drug formulation Substances 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 208000010770 facial weakness Diseases 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 229960003306 fleroxacin Drugs 0.000 description 1
• XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 229940014259 gelatin Drugs 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 239000008202 granule composition Substances 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• 125000006038 hexenyl group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 210000001822 immobilized cell Anatomy 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Chemical group CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Chemical group C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 230000030214 innervation Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000012977 invasive surgical procedure Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000004922 lacquer Substances 0.000 description 1
• 229960003376 levofloxacin Drugs 0.000 description 1
• 208000027905 limb weakness Diseases 0.000 description 1
• 231100000861 limb weakness Toxicity 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 229960002422 lomefloxacin Drugs 0.000 description 1
• ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000009593 lumbar puncture Methods 0.000 description 1
• 210000005230 lumbar spinal cord Anatomy 0.000 description 1
• 210000004705 lumbosacral region Anatomy 0.000 description 1
• YIWJEBPTHXRHQF-LLMLIWGDSA-N lunarine Chemical compound C/1=C\C(=O)NCCCCNCCCNC(=O)\C=C\C(C=C23)=CC=C3O[C@H]3[C@@]\12CCC(=O)C3 YIWJEBPTHXRHQF-LLMLIWGDSA-N 0.000 description 1
• YIWJEBPTHXRHQF-UHFFFAOYSA-N lunarine Natural products C1=CC(=O)NCCCCNCCCNC(=O)C=CC(C=C23)=CC=C3OC3C12CCC(=O)C3 YIWJEBPTHXRHQF-UHFFFAOYSA-N 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 229940126601 medicinal product Drugs 0.000 description 1
• 230000004066 metabolic change Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
• 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 description 1
• 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
• 108091037473 miR-103 stem-loop Proteins 0.000 description 1
• 108091079786 miR-105 stem-loop Proteins 0.000 description 1
• 108091029067 miR-11 stem-loop Proteins 0.000 description 1
• 108091051828 miR-122 stem-loop Proteins 0.000 description 1
• 108091064282 miR-125 stem-loop Proteins 0.000 description 1
• 108091037066 miR-125-1 stem-loop Proteins 0.000 description 1
• 108091062107 miR-125-2 stem-loop Proteins 0.000 description 1
• 108091079767 miR-125-3 stem-loop Proteins 0.000 description 1
• 108091040501 miR-129 stem-loop Proteins 0.000 description 1
• 108091045757 miR-129-3 stem-loop Proteins 0.000 description 1
• 108091090758 miR-129-4 stem-loop Proteins 0.000 description 1
• 108091065139 miR-129-5 stem-loop Proteins 0.000 description 1
• 108091063445 miR-13 stem-loop Proteins 0.000 description 1
• 108091051410 miR-130 stem-loop Proteins 0.000 description 1
• 108091050366 miR-130-1 stem-loop Proteins 0.000 description 1
• 108091054878 miR-130-2 stem-loop Proteins 0.000 description 1
• 108091023685 miR-133 stem-loop Proteins 0.000 description 1
• 108091047467 miR-136 stem-loop Proteins 0.000 description 1
• 108091030496 miR-138 stem-loop Proteins 0.000 description 1
• 108091049773 miR-14 stem-loop Proteins 0.000 description 1
• 108091060382 miR-140 stem-loop Proteins 0.000 description 1
• 108091058688 miR-141 stem-loop Proteins 0.000 description 1
• 108091062895 miR-144 stem-loop Proteins 0.000 description 1
• 108091089860 miR-148 stem-loop Proteins 0.000 description 1
• 108091047577 miR-149 stem-loop Proteins 0.000 description 1
• 108091035696 miR-149-1 stem-loop Proteins 0.000 description 1
• 108091031096 miR-149-2 stem-loop Proteins 0.000 description 1
• 108091057645 miR-15 stem-loop Proteins 0.000 description 1
• 108091072763 miR-151 stem-loop Proteins 0.000 description 1
• 108091033783 miR-153 stem-loop Proteins 0.000 description 1
• 108091059964 miR-154 stem-loop Proteins 0.000 description 1
• 108091027943 miR-16 stem-loop Proteins 0.000 description 1
• 108091091751 miR-17 stem-loop Proteins 0.000 description 1
• 108091069239 miR-17-2 stem-loop Proteins 0.000 description 1
• 108091027698 miR-18-1 stem-loop Proteins 0.000 description 1
• 108091090961 miR-18-2 stem-loop Proteins 0.000 description 1
• 108091023796 miR-182 stem-loop Proteins 0.000 description 1
• 108091029500 miR-183 stem-loop Proteins 0.000 description 1
• 108091047758 miR-185 stem-loop Proteins 0.000 description 1
• 108091047641 miR-186 stem-loop Proteins 0.000 description 1
• 108091058104 miR-187 stem-loop Proteins 0.000 description 1
• 108091023683 miR-187-1 stem-loop Proteins 0.000 description 1
• 108091028751 miR-188 stem-loop Proteins 0.000 description 1
• 108091074848 miR-19 stem-loop Proteins 0.000 description 1
• 108091086416 miR-192 stem-loop Proteins 0.000 description 1
• 108091023127 miR-196 stem-loop Proteins 0.000 description 1
• 108091088515 miR-197 stem-loop Proteins 0.000 description 1
• 108091047177 miR-199 stem-loop Proteins 0.000 description 1
• 108091031898 miR-199-5 stem-loop Proteins 0.000 description 1
• 108091029449 miR-2-1 stem-loop Proteins 0.000 description 1
• 108091087148 miR-20 stem-loop Proteins 0.000 description 1
• 108091066984 miR-20-1 stem-loop Proteins 0.000 description 1
• 108091076199 miR-20-2 stem-loop Proteins 0.000 description 1
• 108091041313 miR-201 stem-loop Proteins 0.000 description 1
• 108091062762 miR-21 stem-loop Proteins 0.000 description 1
• 108091041631 miR-21-1 stem-loop Proteins 0.000 description 1
• 108091044442 miR-21-2 stem-loop Proteins 0.000 description 1
• 108091053008 miR-23 stem-loop Proteins 0.000 description 1
• 108091092825 miR-24 stem-loop Proteins 0.000 description 1
• 108091032978 miR-24-3 stem-loop Proteins 0.000 description 1
• 108091064025 miR-24-4 stem-loop Proteins 0.000 description 1
• 108091085564 miR-25 stem-loop Proteins 0.000 description 1
• 108091080167 miR-25-1 stem-loop Proteins 0.000 description 1
• 108091083056 miR-25-2 stem-loop Proteins 0.000 description 1
• 108091046553 miR-26 stem-loop Proteins 0.000 description 1
• 108091023821 miR-26-1 stem-loop Proteins 0.000 description 1
• 108091045094 miR-26-2 stem-loop Proteins 0.000 description 1
• 108091039812 miR-28 stem-loop Proteins 0.000 description 1
• 108091007431 miR-29 Proteins 0.000 description 1
• 108091024082 miR-32 stem-loop Proteins 0.000 description 1
• 108091074487 miR-34 stem-loop Proteins 0.000 description 1
• 108091092493 miR-34-1 stem-loop Proteins 0.000 description 1
• 108091059780 miR-34-2 stem-loop Proteins 0.000 description 1
• 108091048196 miR-5 stem-loop Proteins 0.000 description 1
• 108091082444 miR-5-1 stem-loop Proteins 0.000 description 1
• 108091078363 miR-5-2 stem-loop Proteins 0.000 description 1
• 108091023818 miR-7 stem-loop Proteins 0.000 description 1
• 108091091149 miR-8 stem-loop Proteins 0.000 description 1
• 108091059456 miR-92-1 stem-loop Proteins 0.000 description 1
• 108091084336 miR-92-2 stem-loop Proteins 0.000 description 1
• 108091032902 miR-93 stem-loop Proteins 0.000 description 1
• 108091023525 miR-95 stem-loop Proteins 0.000 description 1
• 108091086713 miR-96 stem-loop Proteins 0.000 description 1
• 108091070961 miR-96-3 stem-loop Proteins 0.000 description 1
• 108091007422 miR-98 Proteins 0.000 description 1
• 108091039882 miR-99 stem-loop Proteins 0.000 description 1
• 108091045637 miR-99-1 stem-loop Proteins 0.000 description 1
• 108091051043 miR-99-2 stem-loop Proteins 0.000 description 1
• 108091023446 miR158 stem-loop Proteins 0.000 description 1
• 108091088140 miR162 stem-loop Proteins 0.000 description 1
• 108091059821 miR173 stem-loop Proteins 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 238000001000 micrograph Methods 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 210000000337 motor cortex Anatomy 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 230000004118 muscle contraction Effects 0.000 description 1
• 230000004220 muscle function Effects 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 210000001087 myotubule Anatomy 0.000 description 1
• JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
• 229960003808 nadifloxacin Drugs 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 238000013188 needle biopsy Methods 0.000 description 1
• 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
• 230000007830 nerve conduction Effects 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 210000005044 neurofilament Anatomy 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 231100000189 neurotoxic Toxicity 0.000 description 1
• 230000002887 neurotoxic effect Effects 0.000 description 1
• 125000006574 non-aromatic ring group Chemical group 0.000 description 1
• 125000005485 noradamantyl group Chemical group 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical group 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000004043 oxo group Chemical group O=* 0.000 description 1
• 230000003950 pathogenic mechanism Effects 0.000 description 1
• 229960004236 pefloxacin Drugs 0.000 description 1
• FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000005936 piperidyl group Chemical group 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229940116317 potato starch Drugs 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000955 prescription drug Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 201000008752 progressive muscular atrophy Diseases 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 230000004845 protein aggregation Effects 0.000 description 1
• 238000012514 protein characterization Methods 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 239000003306 quinoline derived antiinfective agent Substances 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 102000005912 ran GTP Binding Protein Human genes 0.000 description 1
• 108010005597 ran GTP Binding Protein Proteins 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 229940100486 rice starch Drugs 0.000 description 1
• 229960004062 rufloxacin Drugs 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 206010062261 spinal cord neoplasm Diseases 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 230000003068 static effect Effects 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 239000007940 sugar coated tablet Substances 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 208000031906 susceptibility to X-linked 2 autism Diseases 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 210000001138 tear Anatomy 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 229930192474 thiophene Chemical group 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 229950008187 tosufloxacin Drugs 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 229940043263 traditional drug Drugs 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 210000001364 upper extremity Anatomy 0.000 description 1
• 208000019206 urinary tract infection Diseases 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1